WMSA
ZVRA icon

Weiss Multi-Strategy Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-625
Closed -$145K – 513
2016
Q1 		$145K Hold
625
– – 0.01% 435
2015
Q4 		$199K Sell
625
-1,094
-64% -$297K 0.01% 346
2015
Q3 		$533K Sell
1,719
-156
-8% -$47.8K 0.02% 316
2015
Q2 		$551K Buy
+1,875
New +$409K 0.02% 373

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ZVRA Position: Q2 2016 in Review

Weiss Multi-Strategy Advisers sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 625 shares — an estimated $145K sold.

Weiss Multi-Strategy Advisers first reported a position in ZVRA in Q2 2015 and held it in 4 quarters. The position peaked at $551K in Q2 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Weiss Multi-Strategy Advisers reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 625 Zevra Therapeutics shares in Q2 2016, an estimated $145K.
  • Weiss Multi-Strategy Advisers first reported a position in Zevra Therapeutics in Q2 2015 and held it in 4 quarters.
  • Weiss Multi-Strategy Advisers's Zevra Therapeutics position peaked at $551K in Q2 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.